Published in Healthcare Finance, Tax and Law Weekly, May 7th, 2008
"The completion of enrollment in our pivotal PROPEL trial, a quarter ahead of schedule, is an important milestone for PDX and Allos," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "We gratefully acknowledge the investigators and patients for participating in the study and for their important role in helping to evaluate the safety and efficacy of PDX for the treatment of relapsed or refractory peripheral T-cell lymphoma, a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.